<DOC>
	<DOCNO>NCT02145910</DOCNO>
	<brief_summary>This phase I trial study best dose vemurafenib combine whole brain radiation therapy ( WBRT ) stereotactic radiosurgery ( SRS ) patient v-raf murine sarcoma viral oncogene homolog B ( BRAF ) mutation-positive melanoma brain metastasis . Radiation therapy effective treatment patient brain metastasis . Patients multiple metastasis typically treat WBRT . For patient metastasis , SRS alone use . Vemurafenib may stop growth tumor cell block enzymes need cell growth . Combining radiation treatment vemurafenib melanoma patient brain metastasis may result improved local control prolong survival .</brief_summary>
	<brief_title>Vemurafenib Combined With Whole Brain Radiation Therapy Radiosurgery Patients With BRAF Mutation-Positive Melanoma Brain Metastases</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) vemurafenib combine WBRT SRS determine recommend phase II dose vemurafenib use WBRT SRS patient brain metastasis melanoma . SECONDARY OBJECTIVES : I . To determine local control rate brain metastasis arm . II . To determine rate develop new brain metastasis arm . III . To determine response extracranial disease . IV . To determine overall survival rate progression free survival rate . V. To determine safety tolerability arm . OUTLINE : This dose-escalation study vemurafenib . Patients assign 1 2 arm base number size brain metastasis . All patient receive vemurafenib orally ( PO ) twice daily ( BID ) begin 3-5 day start radiation therapy continue absence disease progression unacceptable toxicity . ARM A : Patients undergo WBRT daily ( QD ) 10 dos . ARM B : Patients undergo SRS ( gamma knife , tomotherapy , cyberknife , megavoltage linear accelerator [ LINAC ] radiation therapy ) day 1 . After completion study therapy , patient follow week 5 7 , 9 13 , month 4 , 6 , 9 , 12 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Histological confirm melanoma ( prior diagnosis okay ) 3 . BRAFV600 mutation positive ( cobas 4800 BRAFV600 mutation test ) 4 . ECOG performance status 0 1 5 . Craniotomy resection allow ( minimum 2 week recovery time surgery initiation protocol therapy ) 6 . Radiographic evidence brain metastasis 7 . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . 8 . Adequate organ function : 1 . WBC ≥ 2000/uL 2 . ANC ≥ 1000/uL 3 . Platelets ≥ 75 x 103/uL 4 . Hemoglobin ≥ 9 g/dL ( ≥ 80 g/L ; may transfuse ) 5 . Creatinine ≤ 2.0 x ULN OR 24hour creatinine clearance &gt; = 50 ml/min 6 . AST/ALT ≤ 2.5 x ULN patient without liver metastasis , ≤ 5 time liver metastasis 7 . Bilirubin ≤ 2.0 x ULN , ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) 8 . Total serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal ( LLN ) 9 . Serum potassium ≥ LLN 10 . Serum sodium ≥ LLN 11 . Serum albumin ≥ LLN 3g/dl 12 . Patients elevate Alkaline Phosphatase due bone metastasis enrol 9 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 26 week last dose investigational product , manner risk pregnancy minimize . Women potential child bear potential include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : 1 . Amenorrhea ≥ 12 consecutive month without another cause , 2 . For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level ≥ 35 mIU/mL . 3 . Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . 4 . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start radiation . Men father potential must use adequate method contraception avoid conception throughout study [ 26 week last dose investigational product ] manner risk pregnancy minimize . 10 . Specific eligibility criterion two arm : 1 . Arm A ( WBRT Vemurafenib ) : Patients 5 brain metastasis , patient brain metastasis exceed limit SRS ( maximum diameter &gt; 4 cm ) . OR Patient one brain metastasis completely resect , resection cavity &gt; 5 cm diameter . 2 . Arm B ( SRS Vemurafenib ) : Patients 4 few brain metastasis . All brain metastasis ≤ 4 cm diameter . Patients one brain metastasis completely resect , resection cavity ≤ 5 cm diameter . OR If patient find progression brain metastasis exceed 4 cm diameter base MRI scan day SRS procedure , patient reassign WBRT arm withdrawn study . The study PI notify . OR If patient find progression brain metastasis exceed 4 lesion base MRI scan day SRS procedure , patient either receive SRS lesion ( 10 lesion ) , reassign WBRT arm , withdrawn study per treat physician . The study PI notify . 1 . Leptomeningeal involvement 2 . Cardiac disease : Congestive heart failure &gt; class II . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . 3 . Pregnancy breastfeed 4 . Documented history cranial hemorrhage 5 . Concurrent administration anticancer therapy administer study 6 . Treatment cytotoxic , investigational drug , target therapy within 2 week prior protocol treatment . 7 . Craniotomy within 2 week protocol treatment . 8 . Prior treatment BRAF MEK inhibitor 9 . Patients prior brain radiation . However , prior WBRT allow Arm B . 10 . QTc &gt; 450 m 11 . Patients history malignancy patient diseasefree less 2 year , exception adequately treat basal squamous cell carcinoma skin , superficial bladder cancer carcinoma situ cervix , AJCC ( version 7.0 ) stage 0 I breast cancer , AJCC ( version 7.0 ) stage I , II prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>